Why PTC Therapeutics Shares Are Gaining Today

PTC Therapeutics Inc PTCT says its APHENITY Phase 3 trial of sepiapterin in adult and pediatric patients with phenylketonuria (PKU) has achieved the primary endpoint.

PKU is a birth defect that causes an amino acid called phenylalanine to build up in the body.

The placebo-controlled portion of the study included 98 patients in the primary analysis population. 

The mean percent Phe reduction in sepiapterin-treated patients was 63%. 

The mean percent Phe reduction was 69% in the subset of classical PKU patients. Minimal reductions in Phe levels were observed in the placebo-treated patients resulting in a highly statistically significant sepiapterin treatment benefit (p<0.0001). 

Sepiapterin was generally well tolerated with no serious adverse events.

"The Phe reductions observed in the placebo-controlled portion of the study are consistent with, and, in some cases, exceed the magnitude of Phe reductions recorded in the open-label portion of the study," said Matthew Klein, Chief Executive Officer.

Price Action: PTCT shares are up 4.02% at $56.38 on the last check Wednesday.

Posted In: BiotechNewsHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...